extensive preclinical evaluation of lutetium-177-labeled psma-specific tracers for prostate cancer
Published 3 years ago • 355 plays • Length 12:45Download video MP4
Download video MP3
Similar videos
-
11:01
lutetium-177: psma guided treatment | #prostatecancer | #markscholzmd | #pcri
-
1:10:05
psma scans & pluvicto (lutetium-177) in 2022 | geoffrey johnson, md, phd | pcri conference 2022
-
0:16
lutetium-177 psma therapy
-
4:48
vision: lu-177-psma-617 in mcrpc
-
2:24
eclipse - a randomized phase 3 trial for 177-lu-psma-i&t in patients with mcrpc
-
1:16
chapter 4: what it's like to have 177 lutetium psma therapy
-
11:49
lutetium-177 (pluvicto) vs. psma-actinium | #markscholzmd #alexscholz #pcri
-
3:50
an update on lutetium-177 for prostate cancer | thomas hope, md & mark moyad, md, mph | 2021 pcri
-
40:03
psma & lutetium-177 in 2022 | eugene kwon, md | diy combat manual for beating prostate cancer part 4
-
5:37
177lu-psma-617 for the early treatment of prostate cancer
-
3:15
living with prostate cancer: lutetium 177 therapy treatment | mercy radiology
-
1:30:29
clinical trials using lutetium 177 and psma targeting radiopharmaceuticals - dr. francois benard
-
6:11
lutetium-177 and bipolar androgen therapy: future game changers in prostate cancer | pcri
-
3:50
the vision trial of psma-617 lutetium-177 for crpc: clinical safety and efficacy
-
1:24
luparp: 177lu-psma-617 and parp inhibitor combination for prostate cancer
-
2:06
chapter 6: outlook on life with 177 lutetium psma therapy
-
1:51
prostate cancer treatment with lutetium 177
-
1:38
dr. sartor on outcomes with 177lu-psma-617 after radium-223 in mcrpc